Literature DB >> 10229426

Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis.

D van der Heijde1, A Calin, M Dougados, M A Khan, S van der Linden, N Bellamy.   

Abstract

To select specific instruments for each domain of the core set for endpoints in ankylosing spondylitis (AS), we gathered all instruments described in the literature to assess the domains chosen as endpoints in AS and sent them to 43 members of the Assessments in Ankylosing Spondylitis (ASAS) Working Group. The following domains were taken into account: function, pain, spinal mobility, patient global assessment, morning stiffness, peripheral joints and entheses, acute phase reactants, x-ray spine, x-ray hips, fatigue. For each instrument the members were asked to judge if the instrument was feasible and relevant. If an instrument was judged to be not feasible or not relevant by more than 50% of the respondents the instrument was deleted from the list. These data were presented during an ASAS workshop and the final decisions were about which instruments to include in the core set. This process was repeated separately for the settings disease controlling antirheumatic therapy (DC-ART), symptom modifying antirheumatic drugs (SMARD) and physical therapy, and clinical record keeping. The response rate to the questionnaire was 72%. For each domain one or more instruments were selected, except for Entheses and Fatigue. The chosen instruments were similar for the 3 above settings. Core sets of specific instruments were selected for the OMERACT filter test for relevance and feasibility. For all these instruments the remaining aspects of the OMERACT filter (truth and discrimination) should be assessed by literature review and if needed by additional research. It is recommended to use these instruments in all research projects in AS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229426

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  69 in total

Review 1.  Spondylarthropathies: options for combination therapy.

Authors:  A M van Tubergen; R B Landewé; S van der Linden
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Conventional treatments for ankylosing spondylitis.

Authors:  M Dougados; B Dijkmans; M Khan; W Maksymowych; Sj van der Linden; J Brandt
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 3.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 4.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 5.  ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis?

Authors:  D van der Heijde; J Braun; R Landewé; J Davis; J Sieper; S van der Linden; M Dougados
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

6.  Fatigue in patients with spondyloarthritis associates with disease activity, quality of life and inflammatory bowel symptoms.

Authors:  Simon M Stebbings; Gareth J Treharne; Katey Jenks; John Highton
Journal:  Clin Rheumatol       Date:  2013-12-10       Impact factor: 2.980

7.  Evaluation of the Turkish version of the Dougados functional index in ankylosing spondylitis.

Authors:  Huseyin T E Ozer; Tunay Sarpel; Bozkurt Gulek; Z Nazan Alparslan; Eren Erken
Journal:  Rheumatol Int       Date:  2005-03-02       Impact factor: 2.631

8.  Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists.

Authors:  R Landewé; B Rump; D van der Heijde; S van der Linden
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

9.  Assessment of therapeutic response in ankylosing spondylitis patients undergoing anti-tumour necrosis factor therapy by whole-body magnetic resonance imaging.

Authors:  Martina Karpitschka; Patrizia Godau-Kellner; Herbert Kellner; Annie Horng; Daniel Theisen; Christian Glaser; Bernhard Brandlhuber; Maximilian Reiser; Sabine Weckbach
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

Review 10.  Clinical assessment and outcome research in spondyloarthritis.

Authors:  Robert B M Landewé; Astrid van Tubergen
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.